NGEN Stock NervGen Pharma (NGEN, $1.86) price moved above its 50-day Moving Average on August 21, 2026
at Tickeron.com
This price move could indicate a change in the trend, and may be a buy signal for investors. A.I.dvisor found 51 similar cases, and were successful. Based on this data, the odds of success are
NGEN in +2.58% Uptrend, rising for three consecutive days on September 11, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where NGEN advanced for three days, in 209 of 253 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
Technical Analysis (Indicators)
Bullish Trend Analysis
NGEN moved above its 50-day moving average on August 21, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for NGEN crossed bullishly above the 50-day moving average on August 26, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 81%.
The Aroon Indicator entered an Uptrend today. In 110 of 148 cases where NGEN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 74%.
Bearish Trend Analysis
The 10-day RSI Indicator for NGEN moved out of overbought territory on September 08, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 similar instances where the indicator moved out of overbought territory. In 21 of the 27 cases, the stock moved lower in the following days. This puts the odds of a move lower at 78%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 40 of 48 cases where NGEN's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 83%.
The Momentum Indicator moved below the 0 level on September 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NGEN as a result. In 74 of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 82%.
The Moving Average Convergence Divergence Histogram (MACD) for NGEN turned negative on September 11, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 40 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 87%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NGEN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
NGEN broke above its upper Bollinger Band on August 21, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 48 (best 1 - 100 worst), indicating steady price growth. NGEN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 62 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (18.762) is normal, around the industry mean (19.994). P/E Ratio (0.000) is within average values for comparable stocks, (27.689). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.527). Dividend Yield (0.000) settles around the average of (0.019) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (427.627).
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NGEN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.